L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis

• Published in: Nutrition & metabolism Vol. 18; no. 1; p. 98
• Main Authors: Wu, Changpeng, Zhu, Mingxing, Lu, Zongliang, Zhang, Yaowen, Li, Long, Li, Na, Yin, Liangyu, Wang, He, Song, Wei, Xu, Hongxia
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 01.11.2021; BioMed Central; BMC
• Subjects: AKT; AKT protein; Antibodies; Atrophy; blood serum; C2C12 cells; Cachexia; Cancer; Cancer cachexia; Care and treatment; Carnitine; Cell differentiation; Colon-26; Complications and side effects; Cytokines; FOXO3 protein; Gastrocnemius muscle; Health aspects; horses; inflammation; Interleukin 1; Interleukin 6; L-Carnitine; Laboratory animals; Levocarnitine; mice; Muscle atrophy; muscles; muscular atrophy; Musculoskeletal system; Myotubes; non-specific serine/threonine protein kinase; nutrition; Protein biosynthesis; Protein kinases; Proteins; Serum levels; siRNA; Skeletal muscle; Stem cells; Transcription factors; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumors; Ubiquitination; Wasting syndrome; Western blotting; China; United States > US

Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. C2C12 cells were differentiate...